Affymax Reports Phase 2 Sub-Analysis Of Hematide™ In Hemodialysis Patients (Medical News Today) |
|
|
Affymax, Inc. (Nasdaq:AFFY) announced data from a post hoc sub-analysis of the Phase 2 clinical trial evaluation of Hematide in chronic renal failure patients undergoing dialysis. read more
|